Abstract The development of nanoparticle agents for MRI-guided radiotherapy is growing at an increasing pace, with clinical trials now underway and many pre-clinical evaluation studies ongoing. Gadolinium iron-oxide-based nanoparticles remain the most clinically advanced to date, although several promising candidates are currently under varying stages development. Goals current future generatio...